Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer

The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Indegene strengthens consulting practice to accelerate life sciences transformation

Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability

Pfizer’s TUKYSA boosts front-line outcomes, extending progression-free survival in HER2+ metastatic breast cancer

Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents

Healthium partners with US-based Tisgenx to bring cardiac innovations to India

This partnership marks a significant step in strengthening Healthium’s position in the cardiac care segment

Supriya Lifescience honoured for outstanding export excellence by Govt. of Maharashtra

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions

Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies

These findings follow positive Phase 3 results presented earlier this year